Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models.

Lin HK, Blake DA, Freeman R, Chen Y, Kim J, Johnson AM, Wells K, Mudigonda A, Liu W, Yadav P, Zeng F, Muhuri A, Min K, Sarkar S, Wang Y, Goyal S, Roberts RC, Christensen E, Ward AB, Heller B, Chun P, Dougan J, Porter CC, Barwick BG, Paulos CM, Yang L, Patgiri A, Thomas SN, Waller EK, Rafiq S.

Open source

DOI: 10.1126/scitranslmed.adt9565
Published: 2026-07-22
Container: Sci Transl Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1126/scitranslmed.adt9565,
  title = {Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models.},
  author = {Lin HK and  Blake DA and  Freeman R and  Chen Y and  Kim J and  Johnson AM and  Wells K and  Mudigonda A and  Liu W and  Yadav P and  Zeng F and  Muhuri A and  Min K and  Sarkar S and  Wang Y and  Goyal S and  Roberts RC and  Christensen E and  Ward AB and  Heller B and  Chun P and  Dougan J and  Porter CC and  Barwick BG and  Paulos CM and  Yang L and  Patgiri A and  Thomas SN and  Waller EK and  Rafiq S.},
  year = {2026},
  journal = {Sci Transl Med},
  doi = {10.1126/scitranslmed.adt9565},
  url = {https://doi.org/10.1126/scitranslmed.adt9565}
}

RIS

TY  - JOUR
TI  - Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models.
AU  - Lin HK
AU  -  Blake DA
AU  -  Freeman R
AU  -  Chen Y
AU  -  Kim J
AU  -  Johnson AM
AU  -  Wells K
AU  -  Mudigonda A
AU  -  Liu W
AU  -  Yadav P
AU  -  Zeng F
AU  -  Muhuri A
AU  -  Min K
AU  -  Sarkar S
AU  -  Wang Y
AU  -  Goyal S
AU  -  Roberts RC
AU  -  Christensen E
AU  -  Ward AB
AU  -  Heller B
AU  -  Chun P
AU  -  Dougan J
AU  -  Porter CC
AU  -  Barwick BG
AU  -  Paulos CM
AU  -  Yang L
AU  -  Patgiri A
AU  -  Thomas SN
AU  -  Waller EK
AU  -  Rafiq S.
PY  - 2026
JO  - Sci Transl Med
DO  - 10.1126/scitranslmed.adt9565
UR  - https://doi.org/10.1126/scitranslmed.adt9565
ER  -

APA

HK, L., DA, B., R, F., Y, C., J, K., AM, J., K, W., A, M., W, L., P, Y., F, Z., A, M., K, M., S, S., Y, W., S, G., RC, R., E, C., AB, W., B, H., P, C., J, D., CC, P., BG, B., CM, P., L, Y., A, P., SN, T., EK, W., & S., R. (2026). Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models.. Sci Transl Med. https://doi.org/10.1126/scitranslmed.adt9565

Source records

europe-pmc · retrieved 2026-09-25T14:38:33.795Z